Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): Defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease

Blood

Volumn 108, Issue 7, 2006, Pages 2316-2323

  Marcenaro, Stefania ^b   Gallo, Federico ^b   Martini, Stefania ^b   Santoro, Alessandra ^b   Griffiths, Gillian M ^b   Aricó, Maurizio ^b   Moretta, Lorenzo ^b   Pende, Daniela ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY; PERFORIN;

ARTICLE; CELL CULTURE; CELL FUNCTION; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS LINKING; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXICITY; DENDRITIC CELL; EPSTEIN BARR VIRUS; FEMALE; GENE; GENE MUTATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; HUMAN CELL; INFANT; MALE; MUNC13 4 GENE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL;

EID: 33749349937     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-015693     Document Type: Article

References (53)

1. Farquhar J, Claireaux A. Familial haemophagocytic reticulosis. Arch Dis Child. 1952;27:519-525.
2. Henter JI, Horne AC, Aricó M, et al. Diagnostic and Therapeutic Guidelines for Hemophagocytic Lymphohistiocytosis. Ped Blood Cancer. In press.
3. Aricò M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 1996;10:197-203.
4. Imashuku S, Hibi S, Sako M, et al. Heterogeneity of immune markers in hemophagocytic lymphohistiocytosis: comparative study of 9 familial and 14 familial inheritance-unproved cases. J Pediatr Hematol Oncol. 1998;20:207-214.
5. Kanda Y, Tanaka Y, Shirakawa K, et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant. 1998;22:751-754.
6. Schneider EM, Lorenz I, Muller-Rosenberger M, et al. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood. 2002;100:2891-2898.
7. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998;12:435-444.
8. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286:1957-1959.
9. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115:461-473.
10. Ishii E, Ueda I, Shirakawa R, et al. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. Blood. 2005;105:3442-3448.
11. Zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005;14:827-834.
12. Uellner R, Zvelebil MJ, Hopkins J, et al. Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J. 1997;16:7287-7296.
13. Lowin B, Peitsch MC, Tschopp J. Perforin and granzymes: crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity. Curr Top Microbiol Immunol. 1995;198:1-24.
14. Trambas CM, Griffiths GM. Delivering the kiss of death. Nat Immunol. 2003;4:399-403.
15. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002;2:735-747.
16. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature. 1995;377:446-448.
17. Neeft M, Wieffer M, de Jong AS, et al. Munc13-4 is an effector of Rab27a and controls secretion of lysosomes in hematopoietic cells. Mol Biol Cell 2005;16:731-741.
18. Shirakawa R, Higashi T, Tabuchi A, et al. Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets. J Biol Chem. 2004; 279:10730-10737.
19. Ménasché G, Pastural E, Feldmann J, et al. Mutations in RAB27A cause Griselli syndrome associated with hemophagocytic syndrome. Nat Genet. 2000;25:173-176.
20. Arico M, Danesino C, Pende D, Moretta L. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol 2001;114:761-769.
21. Zamai L, Ahmad M, Bennet IM, et al. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998;188:2375-2380.
22. Screpanti V, Wallin RP, Grandien A, Ljunggren HG. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol. 2005; 42:495-499.
23. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359-393.
24. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol. 2002;3:6-8.
25. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004;23:255-259.
26. Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Different checkpoints in human NK-cell activation. Trends Immunol. 2004;25:670-676.
27. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223.
28. Wu J, Song Y, Bakker ABH, et al. An activating immunoreceptor complex formed by NKG2D and DAP 10. Science. 1999;285:730-732.
29. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002;62:6178-6186.
30. Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198:557-567.
31. Moretta A, Bottino C, Vitale M, et al. Receptors for HLA-class I molecules in human natural killer cells. Annu Rev Immunol. 1996;14:619-648.
32. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 1998;17:875-904.
33. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217-251.
34. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795-799.
35. Bottino C, Moretta L, Pende D, Vitale M, Moretta A. Learning how to discriminate between friends and enemies, a lesson from natural killer cells. Mol Immunol. 2004;41:569-575.
36. Della Chiesa M, Vitale M, Carlomagno S, et al. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors [published correction appears in Eur J Immunol. 2003;33:2947]. Eur J Immunol. 2003;33:1657-1666.
37. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol. 2002;2:957-965.
38. Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri, MA. NK cell and DC interactions. Trends Immunol. 2004;2547-2552.
39. Della Chiesa M, Sivori S, Castriconi R, Marcenaro E, Moretta A. Pathogen-induced private conversations between natural killer and dendritic cells. Trends Microbiol. 2005;13:128-136.
40. Moretta A. The dialogue between human natural killer cells and dendritic cells. Curr Opin Immunol. 2005;17:306-311.
41. Moretta L, Bottino C, Pende D, et al. Natural killer cells: their origin, receptors and functional role in immune responses. Eur J Immunol. 2002;32:1205-1211.
42. Corner BG, Smith HR, French AR, et al. Coordinated expression of cytokines and chemokines by NK cells during murine cytomegalovirus infection. J Immunol. 2004;172:3119-3131.
43. Aricò M, Allen M, Brusa S, et al. Haemophagocytic lymphohistiocytosis: proposal of a diagnostic algorithm based on perforin expression. Br J Haematol. 2002;119:180-188.
44. Kogawa K, Lee SM, Villanueva J, et al. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002;99:61-66.
45. Henter JI, Samuelsson-Horne A, Aricò M, et al. Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100:2367-2373.
46. Pende D, Parolini S, Pessino A, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med. 1999;190:1505-1516.
47. Trambas C, Gallo F, Pende D, et al. A single acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin. Blood. 2005;106:932-937.
48. Penack O, Gentilini C, Fischer L, et al. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia. 2005;19:835-840.
49. Santoro A, Cannella S, Bossi G, et al. Novel Munc13-4 mutations in children and young adult patients with hemophagocytic lymphohistiocytosis. J Med Genet. 2006 Jul 6; Epub ahead of print.
50. Vitale M, Della Chiesa M, Carlomagno S, et al. NK-dependent maturation is mediated by TNFα and IFNγ released upon engagement of the NKp30 triggering receptor. Blood. 2005;106:566-571.
51. Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med. 2005;202:1001-1012.
52. Duprè L, Andolfi G, Tangye SG, et al. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood. 2005;105:4383-4389.
53. Parolini S, Bottino C, Falco M, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med. 2000;192:337-346.